Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Diagnosis and Treatment of Cancer Using Histone Deacetylase Inhibitors and Radiolabeled Metaiodobenzylguanidine

Posted Mar 22 2010 5:00pm

Description of Invention:
Pheochromocytoma is a neuroendocrine tumor of the adrenal glands. Pheochromocytoma patients display the signs and symptoms of those of sympathetic nervous system hyperactivity. Up to 36% of patients worldwide with pheochromocytoma develop metastatic disease and have a 5-year survival rate of approximately 50% after diagnosis. Patients with metastatic pheochromocytoma exhibit excessive levels of circulating catecholamines, which results in increased risk of strokes, cardiac arrhythmias, and hypertensive complications. Current treatments for malignant pheochromocytoma include targeted radiation using [131I]-metaiodobenzylguanidine ([131I]-MIBG), cytotoxic chemotherapy, octreotide, tumor hemoembolization, etc. The success of these treatments varies based on the sites and growth rate of metastatic lesions.

The present invention provides a method for treating a mammalian tumor with a histone deacetylase inhibitor (HDACi), and followed by administering [131I]-MIBG. Methods of diagnosis and imaging of mammalian tumors are also disclosed. These findings suggest that HDACi could enhance the therapeutic efficacy of [131I]-MIBG treatment in patients with malignant pheochromocytoma.

Applications:
Diagnosis and therapeutic for treating cancer, such as pheochromocytoma

Development Status:
Pre-clinical stage of development

Inventors:
Karel Pacak (NICHD)


Patent Status:
HHS, Reference No. E-299-2009/0
US, Application No. 61/260,991 filed 13 Nov 2009


Relevant Publication:
  1. Manuscript submitted


Licensing Status:
Available for licensing.

Collaborative Research Opportunity:
The National Institute of Child Health and Human Development, Reproductive Biology and Adult Endocrinology Branch, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize [131I]-MIBG treatment of malignant/metastatic pheochromocytoma, paraganglioma, and neuroblastoma; also [123/131I]-MIBG scintigraphy - in all situations histone deacetylase to be used before MIBG is used. Please contact Joseph Conrad, Ph.D. at 301-435-3107 or jmconrad@mail.nih.gov for more information. Click here to view the NICHD collaborative opportunity announcement.


Portfolios:
Cancer
Cancer - Diagnostics
Cancer - Therapeutics



For Additional Information Please Contact:
Betty Tong Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: tongb@mail.nih.gov
Phone: 301-594-6565
Fax: 301-402-0220


Ref No: 2074

Updated: 03/2010

Post a comment
Write a comment:

Related Searches